The prognostic signatures evaluated provided significant information to help determine appropriate candidates consisting of patients with ER-positive, ERBB2-negative breast cancer, for whom chemotherapy and extended endocrine therapy might not be indicated. This evidence concerns the gene ESR1 and breast carcinoma.